Biocept Inc. (BIOC)

0.96
NASDAQ : Health Technology
Prev Close 0.99
Day Low/High 0.95 / 0.99
52 Wk Low/High 0.66 / 3.88
Avg Volume 1.49M
Exchange NASDAQ
Shares Outstanding 23.02M
Market Cap 22.82M
EPS -9.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept Reports Second Quarter 2019 Financial Results

Biocept Reports Second Quarter 2019 Financial Results

- Second quarter 2019 revenues increased 45% and commercial samples increased 26% over the second quarter of 2018

Biocept To Release Second Quarter 2019 Financial Results And Host Investor Conference Call On August 12, 2019

Biocept To Release Second Quarter 2019 Financial Results And Host Investor Conference Call On August 12, 2019

SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Biocept, Inc.

Biocept Announces Laboratory Services Provider Agreement With BeaconLBS®

Biocept Announces Laboratory Services Provider Agreement With BeaconLBS®

BeaconLBS now offers Biocept's Target Selector™ testing for liquid biopsy as part of its laboratory management network in the United States

Biocept Announces Commercial Launch Of Target Selector™ NGS Breast Panel, The Company's Second Multi-Gene Tumor-Specific Panel

Biocept Announces Commercial Launch Of Target Selector™ NGS Breast Panel, The Company's Second Multi-Gene Tumor-Specific Panel

Biocept continues to expand its commercial offering for breast cancer and remains the only liquid biopsy provider to offer single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis

Biocept To Present At The 9th Annual LD Micro Invitational Conference On June 4

Biocept To Present At The 9th Annual LD Micro Invitational Conference On June 4

SAN DIEGO, June 3, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer,...

Biocept Awarded Patent In China For Its Circulating Tumor Cell Platform Expanding Intellectual Property Estate To 33 Issued Patents Globally

Biocept Awarded Patent In China For Its Circulating Tumor Cell Platform Expanding Intellectual Property Estate To 33 Issued Patents Globally

Newly issued patent in China covers use of antibody cocktails in combination with a microchannel to capture rare cells such as circulating tumor cells (CTCs) from any biological sample of interest

Biocept Announces Clinical Validation And Commercial Launch Of Its Target Selector™ Multi-Gene Liquid Biopsy Panel For Lung Cancer

Biocept Announces Clinical Validation And Commercial Launch Of Its Target Selector™ Multi-Gene Liquid Biopsy Panel For Lung Cancer

Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis

Biocept Reports First Quarter 2019 Financial Results

Biocept Reports First Quarter 2019 Financial Results

- Revenues increased 27% compared to the first quarter of 2018

Biocept To Release First Quarter 2019 Financial Results And Host Investor Conference Call On May 8, 2019

Biocept To Release First Quarter 2019 Financial Results And Host Investor Conference Call On May 8, 2019

SAN DIEGO, May 1, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of...

Biocept Reports 2018 Fourth Quarter And Full Year Financial Results

Biocept Reports 2018 Fourth Quarter And Full Year Financial Results

Progress made implementing the Company's commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018

Biocept Broadens Commercial Focus Of Its Target Selector Liquid Biopsy Platform To Include Urology Market Segment

Biocept Broadens Commercial Focus Of Its Target Selector Liquid Biopsy Platform To Include Urology Market Segment

Expansion of Biocept's EmpowerTC™ offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer

Biocept To Release 2018 Fourth Quarter And Full Year Financial Results And Host Investor Conference Call On March 28, 2019

Biocept To Release 2018 Fourth Quarter And Full Year Financial Results And Host Investor Conference Call On March 28, 2019

SAN DIEGO, March 21, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer...

Biocept Awarded Patent In Japan For The Capture Of Rare Cells Including CTCs From Any Biological Sample Of Interest With A Microchannel Device

Biocept Awarded Patent In Japan For The Capture Of Rare Cells Including CTCs From Any Biological Sample Of Interest With A Microchannel Device

Biocept expands intellectual property position to 32 issued patents globally for its highly sensitive methods for detecting cancer biomarkers in blood and other specimen types

Biocept Announces Pricing Of $8.2 Million Registered Direct Offering

Biocept Announces Pricing Of $8.2 Million Registered Direct Offering

SAN DIEGO, March 15, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of...

Biocept Expands Its Pathology Partnership Offering For Liquid Biopsy With The Addition Of Several Key Services

Biocept Expands Its Pathology Partnership Offering For Liquid Biopsy With The Addition Of Several Key Services

Proprietary platform enables local pathologists to participate in liquid biopsy testing with new capabilities to evaluate circulating tumor cells (CTCs) and expanded menu of biomarkers

Biocept's Liquid Biopsy Test For ESR1 Biomarker Detection To Be Featured In Poster Presentation At The 2019 AACR Annual Meeting

Biocept's Liquid Biopsy Test For ESR1 Biomarker Detection To Be Featured In Poster Presentation At The 2019 AACR Annual Meeting

Analytical validation of liquid biopsy test for ESR1 mutations offers potential clinical utility by identifying biomarkers that may drive acquired resistance to hormone therapy in breast cancer

Biocept And Providence Saint John's Health Center Collaborate To Evaluate Cerebrospinal Fluid For Use With Liquid Biopsy Testing In Metastatic Cancer

Biocept And Providence Saint John's Health Center Collaborate To Evaluate Cerebrospinal Fluid For Use With Liquid Biopsy Testing In Metastatic Cancer

Saint John's and John Wayne Cancer Institute to validate use of cerebrospinal fluid with the Company's Target Selector™ assay platform in patients with known or suspected brain metastases

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) stock is surging in mid-morning trading on Tuesday after the company announced an agreement with Blue Cross Blue Shield of Illinois.

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings...

Biocept To Present At 2015 Aegis Growth Conference

Biocept To Present At 2015 Aegis Growth Conference

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to...

Biocept Announces Participation In MultiPlan's Networks

Biocept Announces Participation In MultiPlan's Networks

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that it has entered into an agreement with MultiPlan,...

Biocept Secures Agreements With Preferred Provider Organizations Stratose And Galaxy Health Network For Its Proprietary Blood-Based Oncology Diagnostic Assays

Biocept Secures Agreements With Preferred Provider Organizations Stratose And Galaxy Health Network For Its Proprietary Blood-Based Oncology Diagnostic Assays

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces additional agreements with preferred...

Biocept Expands U.S. Microchannel Patent Protection

Biocept Expands U.S. Microchannel Patent Protection

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces the allowance of U.

Biocept's Liquid Biopsy Lung Cancer Target Selector Assay To Be Featured At World Conference On Lung Cancer

Biocept's Liquid Biopsy Lung Cancer Target Selector Assay To Be Featured At World Conference On Lung Cancer

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that clinical data from a study conducted with...

TheStreet Quant Rating: E+ (Sell)